The Health Sciences Authority (HSA) reported on Monday that there have been four complaints of minor adverse effects in the two weeks following the introduction of the Nuvaxovid COVID-19 vaccine in Singapore (Jun 27).
They consist of chest discomfort, dizziness, rash, and vasculitis (blood vessel inflammation).
These are well-known side effects of vaccinations, according to HSA, and are generally consistent with what was observed in the clinical studies.
Nuvaxovid is a vaccine used to prevent coronavirus disease 2019 (COVID-19) in people aged 18 and up. Nuvaxovid contains a lab-created version of a protein found on the surface of SARS-CoV-2 (the spike protein).
A protein-based vaccination candidate for COVID-19 has been created by Novavax using the genetic sequence of the virus that causes COVID-19, the first strain of SARS-CoV-2. According to a prior statement by Novavax, the vaccine may be stored between 2 and 8 degrees Celsius, allowing for the utilization of existing cold chain and vaccine supply systems.
The Nuvaxovid COVID-19 vaccine from Novavax has been given temporary approval by Singapore's Health Sciences Authority (HSA), the company said on Monday (Feb 14).
On February 3 of this year, the vaccine was approved for use in anyone 18 and older. Two doses of 5 micrograms each are given three weeks apart as part of the vaccination schedule.
As of May 31, 2,792 doses of the Nuvaxovid vaccination had been given to the general public in Singapore, according to a safety update from the HSA.
The COVID-19 vaccine distribution began on December 30, 2020, and ended on May 31, 2022, making this the 12th update of its kind.
Serious adverse events include those that lead to hospitalization, a serious disease, or death, among other outcomes.
Although continuing international clinical trials of Nuvaxovid have documented a "limited number" of instances, HSA stated that it has not yet received any reports of myocarditis, an inflammatory disorder of the heart.
Anaphylaxis, myocarditis (inflammation of the heart muscles), pericarditis (inflammation of the outer membrane of the heart), and cerebral venous thrombosis (CVT) have steady incidence rates of adverse events of interest (AESIs). Since the last update in February 2022, there have been no fresh discoveries.
The danger of myocarditis cannot be completely eliminated, but the authorities stated that in the context of Singapore, the advantages of the Nuvaxovid vaccine continue to outweigh the disadvantages.
As part of the national vaccination campaign, HSA issued interim authorization for the Nuvaxovid vaccine in February. Those who have not received their primary doses or booster shots are eligible to use them.
